169 filings
Page 6 of 9
8-K
jh13jf42lfw3kr451y
25 May 21
Keros Therapeutics Announces Issuance of U.S. Patent for Use of Therapeutic Proteins in Treatment of Musculoskeletal Disorders
8:04am
8-K
9cxvjf04loi54 bsspww
14 May 21
Other Events
8:01am
8-K
ntjd iad12go1e7jjo9z
12 May 21
Keros Therapeutics to Present at the Virtual 26th Annual Congress of the European Hematology Association
4:03pm
8-K
skj6 ckaehuw
6 May 21
May 2021 Corporate Presentation
4:20pm
8-K
itnhovgwrbpzbj6w5h
6 May 21
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
4:03pm
S-3ASR
v18 ab46mc
3 May 21
Automatic shelf registration
4:33pm
DEFA14A
wwa au0r1q070v
19 Apr 21
Additional proxy soliciting materials
4:17pm
DEF 14A
6kjscxh jeo
19 Apr 21
Definitive proxy
4:15pm
8-K
5b8emj7
25 Mar 21
March 2021 Corporate Presentation
8:31am
10-K
mxde5m
25 Mar 21
Annual report
8:23am
8-K
w786w
25 Mar 21
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
8:07am
8-K
h8wfr02qgcy 49g
5 Mar 21
Other Events
8:03am
8-K
rg1xrmmo5nb4ngbnh5c
2 Mar 21
Keros Therapeutics to Present at the H.C. Wainwright Global Life Sciences 2021 Virtual Conference
8:06am
8-K
nb906rk eyz8w3bckun
17 Feb 21
Keros Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
8:06am
S-8
fca0e2y nx0
15 Jan 21
Registration of securities for employees
4:28pm
8-K
k6gg85iw73
21 Dec 20
Keros Therapeutics Announces Addition to NASDAQ Biotechnology Index
8:04am
8-K
5voc84cugdk6uq
17 Dec 20
Keros Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors
8:03am
8-K
6lz0l eo8
7 Dec 20
Other Events
8:11am
8-K
kbkn0
17 Nov 20
Keros Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:03pm